Predicting major outcomes in type 1 diabetes: a model development and validation study

Diabetologia

Volumn 57, Issue 11, 2014, Pages 2304-2314

  Soedamah Muthu, Sabita S ^a   Vergouwe, Yvonne ^b,c   Costacou, Tina ^d   Miller, Rachel G ^d   Zgibor, Janice ^d   Chaturvedi, Nish ^e   Snell Bergeon, Janet K ^f   Maahs, David M ^f   Rewers, Marian ^f   Forsblom, Carol ^g,h   Harjutsalo, Valma ^g,h,i   Groop, Per Henrik ^g,h,j   Fuller, John H ^k   Moons, Karel G M ^b   Orchard, Trevor J ^d  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f UNIVERSITY OF COLORADO DENVER   (United States)

^g FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^j BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Development; Discrimination; External validation; Major outcomes; Predict; Prognostic model; Risk; Type 1 diabetes; Validation

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AMPUTATION; ARTICLE; BLINDNESS; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE DURATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERMEDIATE RISK POPULATION; ISCHEMIC HEART DISEASE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; VALIDATION STUDY; METABOLISM; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; THEORETICAL MODEL;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MODELS, THEORETICAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84919924352     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3358-x     Document Type: Article

References (44)

1. Stephenson J, Fuller JH (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285
2. Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ (1991) Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 34:584–589
3. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55:1463–1469
4. Ahola AJ, Saraheimo M, Forsblom C, Hietala K, Sintonen H, Groop P-H (2010) Health-related quality of life in patients with type 1 diabetes—association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant 25:1903–1908
5. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the General Practice Research Database. Diabetes Care 29:798–804
6. Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321
7. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986
8. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
9. Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med 169:1307–1316
10. Nathan DM (2012) Understanding the long-term benefits and dangers of intensive therapy of diabetes. Arch Intern Med 172:769–770
11. Davis WA, Davis TME (2010) Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 90:e75–e78
12. Zgibor JC, Ruppert K, Orchard TJ et al (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 88:314–321
13. Groop P-H, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658
14. Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697
15. Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116–1124
16. Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024
17. Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Diabetes 52:2833–2839
18. Soedamah-Muthu SS, Chaturvedi N, Toeller M et al (2004) Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27:530–537
19. Sjolie AK, Stephenson J, Aldington S et al (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104:252–260
20. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227
21. Hanas R, John G (2010) 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 33:1903–1904
22. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
23. Rubin DB, Schenker N (1991) Multiple imputation in health-care databases: an overview and some applications. Stat Med 10:585–598
24. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387
25. Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942
26. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546
27. Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248–1254
28. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
29. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847
31. Game FL, Jones AF (2001) Coronary heart disease risk assessment in diabetes mellitus—a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 18:355–359
32. Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K (2001) A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 8:291–297
33. Kaptoge S, Di Angelantonio E, Pennells L et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320
34. Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD (2004) Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23:2567–2586
35. Steyerberg EW (2005) Local applicability of clinical and model-based probability estimates. Med Decis Mak 25:678–680
36. Tielemans SM, Soedamah-Muthu SS, de Neve M et al (2013) Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 56:82–91
37. Delahanty LM, Nathan DM, Lachin JM et al (2009) Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 89:518–524
38. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473
39. Choi SC (1998) Sample size in clinical trials with dichotomous endpoints: use of covariables. J Biopharm Stat 8:367–375
40. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C (2003) Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289:2554–2559
41. Rosenson RS, Fioretto P, Dodson PM (2011) Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218:13–18
42. Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77:S26–S30
43. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625
44. Tanaka S, Tanaka S, Iimuro S et al (2013) Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 36:1193–1199